News

The Phase II trial is a double-blinded, randomized, dose-ranging, placebo-controlled study designed to assess cobiprostone’s efficacy and safety for preventing non-steroidal anti-inflammatory drugs-induced ulcers in patients with arthritis.

This commitment is part of Tekmira’s manufacturing relationship with Alnylam through Phase II clinical development for RNAi therapeutics that utilize Tekmira’s stable nucleic acid-lipid particles (SNALP) technology, including

Three separate sources of growth are expected to drive Monogram’s 2009 revenues: Increased sales of Trofile due to its clinically proven high level of sensitivity for selecting appropriate

Following a controlled allergen challenge in patients with mild asthma, TPI ASM8 did not demonstrate statistical significance in the primary efficacy endpoint – late asthmatic response. However, trends

The goal of the trial was to demonstrate and measure the ability of Zetiq’s technology to accurately diagnose the presence of cervical cancer cells and the stage of

The recent strengthening of the dollar will continue to have adverse effect on European Diagnostics sales denominated in the Euro. Natural hedging programs mitigate the impact of currency

PrepaCyte-CB provides public and private cord blood banks a simple and cost-effective method for processing umbilical cord blood to obtain potentially therapeutic cells – total nucleated cells and

Kendle said that its India operations provide customers access to the full spectrum of early and late stage clinical development services conducted by staff experienced in running all

Mr Steed has most recently served as head of biology for Serenex, which was acquired in April 2008 by Pfizer. Albert Bender, CEO of NanoVector, said: “We are